multiple sclerosis

German Merck finally gets yes for MS drug Mavenclad
German Merck finally gets yes for MS drug Mavenclad
Biopharma Dive
FDA
Merck KGaA
Mavenclad
MS
multiple sclerosis
Flag link:
Still hunting a blockbuster, Merck KGaA scores a win in the FDA approval column — more than 13 years in the making
Still hunting a blockbuster, Merck KGaA scores a win in the FDA approval column — more than 13 years in the making
Endpoints
FDA
Merck KGaA
cladribine
MA
multiple sclerosis
Flag link:
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Fierce Biotech
Celgene
ozanimod
MS
multiple sclerosis
Flag link:
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A
Flag link:
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Xconomy
Celgene
Bristol-Myers Squibb
Europe
FDA
M&A
MS
multiple sclerosis
ozanimod
Flag link:
FDA Accepts for Review Alkermes' and Biogen's NDA for Multiple Sclerosis Drug
FDA Accepts for Review Alkermes' and Biogen's NDA for Multiple Sclerosis Drug
CP WIre
Alkermes
Biogen
diroximel fumarate
MS
multiple sclerosis
Flag link:
Blocking brain inflammation in multiple sclerosis with gut immune cells
Blocking brain inflammation in multiple sclerosis with gut immune cells
Fierce Biotech
inflammation
MS
multiple sclerosis
Flag link:
Alkermes/Biogen hope for less tummy trouble with new MS pill
Alkermes/Biogen hope for less tummy trouble with new MS pill
Pharmaforum
Alkermes
Biogen
MS
multiple sclerosis
Vumerity
Flag link:
Novartis confident in Gilenya despite FDA call out
Novartis confident in Gilenya despite FDA call out
Biopharma Dive
Novartis
Gilenya
MS
multiple sclerosis
Flag link:
Mylan's generic Copaxone wins in court, but market barriers remain
Mylan's generic Copaxone wins in court, but market barriers remain
Biopharma Dive
Teva Pharmaceutical
Copaxone
patents
MS
multiple sclerosis
Flag link:
Merck KGaA posts mixed data from their big PhIIb MS study on evobrutinib — spurring plenty of questions
Merck KGaA posts mixed data from their big PhIIb MS study on evobrutinib — spurring plenty of questions
Endpoints
Merck KGaA
evobrutinib
MS
multiple sclerosis
Flag link:
Can Sanofi's new long-term Lemtrada data amp up sales in a crowded MS field?
Can Sanofi's new long-term Lemtrada data amp up sales in a crowded MS field?
Fierce Pharma
Sanofi
Lemtrada
MS
multiple sclerosis
Flag link:
Roche and Novartis Strengthen Their Presence in the MS Market
Roche and Novartis Strengthen Their Presence in the MS Market
BioSpace
Genentech
Roche
Ocrevus
Novartis
siponimod
FDA
MS
multiple sclerosis
Flag link:
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
CP Wire
Celgene
ozanimod
multiple sclerosis
Flag link:
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
Celgene
ozanimod
multiple sclerosis
Flag link:
Novartis bets PRV on its next big multiple sclerosis drug — eyes US, EU approvals in ’19
Novartis bets PRV on its next big multiple sclerosis drug — eyes US, EU approvals in ’19
Endpoints
Novartis
siponimod
MS
multiple sclerosis
Europe
Flag link:
Servier drops GeNeuro’s multiple sclerosis drug after midphase miss
Servier drops GeNeuro’s multiple sclerosis drug after midphase miss
Fierce Biotech
Servier
GeNeuro
MS
multiple sclerosis
GNbAC1
Flag link:
Federal court rules Ampyra patents invalid, Acorda stock sinks 25%
Federal court rules Ampyra patents invalid, Acorda stock sinks 25%
Biopharma Dive
Acorda Therapeutics
MS
multiple sclerosis
AMPYRA
patents
Flag link:
MS Society protests NICE rejection of Ocrevus for primary progressive MS
MS Society protests NICE rejection of Ocrevus for primary progressive MS
BioCentury
NICE
UK
MS
multiple sclerosis
Ocrevus
ocrelizumab
Roche
Flag link:
Biogen, Teva benefit as payers ease up on multiple sclerosis meddling: analyst
Biogen, Teva benefit as payers ease up on multiple sclerosis meddling: analyst
Fierce Pharma
Biogen
Teva Pharmaceutical
MS
multiple sclerosis
payers
Flag link:

Pages